Court Says FibroGen’s UK Roxadustat Patents Are Invalid
Ruling Favors Akebia/Otsuka’s Rival Anemia Drug
A complex and weighty judgment from the High Court regarding a new class of anemia compounds tackles a range of thorny patent law issues including obviousness, insufficiency and indirect infringement.
You may also be interested in...
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.